Related Experiment Video
Updated: Mar 27, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Incidental detection of PDAC via 18F-PSMA PET/CT in a patient with recurrent prostate cancer. A case report
Giordano Savelli1, Mattia Bonacina1, Alberto Soffientini1
1Nuclear Medicine "Alessandra Bono", Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.
Introduction:
Prostate specific membrane antigen (PSMA) is a type II transmembrane protein overexpressed in the neovasculature of some pancreatic ductal adenocarcinoma (PDAC). PET/CT can detect this expression and has now become an essential tool in this context. However, this antigen can also be expressed by other neoplasms. While this may create diagnostic uncertainty, it could also open therapeutic opportunities.
Clinical Case:
Here we describe a case in which a PET/CT performed to restage a patient with prostate adenocarcinoma experiencing biochemical recurrence revealed the coexistence of a PDAC.
Literature Review:
A literature review aimed to summarize the bibliographic evidence on the use of this technique in this setting, which is relatively uncommon.
Conclusion:
Prostate-specific membrane antigen can be overexpressed in PDACs. This finding may offer potential for theranostic applications.
Insights
Prostate-specific membrane antigen (PSMA) is found in some pancreatic cancers. PET/CT scans detecting PSMA expression can reveal both prostate and pancreatic cancer, offering theranostic potential.
Area of Science:
- Oncology
- Nuclear Medicine
- Molecular Imaging
Background:
- Prostate-specific membrane antigen (PSMA) is a transmembrane protein.
- PSMA is overexpressed in the neovasculature of some pancreatic ductal adenocarcinomas (PDAC).
- Positron Emission Tomography/Computed Tomography (PET/CT) detects PSMA expression, aiding in diagnosis.
